文献速递淋巴瘤

慢性淋巴细胞白血病中BCAT1异常表达增强MTOR活性并加速疾病进展

Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2024-10-25

对117例流式分选CLL进行mRNA/cDNA表达谱分析,发现BCAT1在del17p/TP53mut和12三体CLL中优先表达,且正常淋巴结B细胞不表达。BCAT1高表达者p-S6K归一化MTOR活性约高两倍,对Venetoclax诱导凋亡敏感性降低;任何可检测BCAT1蛋白独立关联中位生存缩短(125个月对296个月,p<0.0001)。

要点

  • BCAT1在del17p/TP53mut CLL中表达率66%,在12三体CLL中77%,正常淋巴结B细胞不表达。
  • BCAT1高表达CLL的p-S6K归一化MTOR活性约高两倍,且对Venetoclax诱导凋亡敏感性降低。
  • 任何可检测BCAT1蛋白独立关联中位生存缩短:125个月对296个月(p<0.0001)。

核心结论

  • BCAT1异常表达增强MTOR活性并加速慢性淋巴细胞白血病疾病进展。
  • BCAT1在del17p/TP53mut或12三体CLL中优先表达,正常淋巴结B细胞不表达。
  • BCAT1高表达者MTOR活性约高两倍且对Venetoclax诱导凋亡敏感性降低。
  • 任何可检测BCAT1蛋白独立关联中位生存缩短(125个月对296个月,p<0.0001)。

研究设计与样本

  • 对N=117例流式分选CLL进行mRNA/cDNA基因表达谱分析。
  • 通过广泛验证确认BCAT1在del17p/TP53mut(66%)或12三体(77%)CLL中的优先表达。
  • 在原发性CLL细胞中进行稳态代谢组学和重同位素代谢示踪。
  • 使用三个CLL来源细胞系进行BCAT1破坏后的体外生长实验。

主要发现

  • BCAT1在del17p/TP53mut CLL中表达率66%,在12三体CLL中表达率77%。
  • 正常人类淋巴结分离的B细胞不表达BCAT1。
  • BCAT1高表达原发性CLL在sIgM交联前后p-S6K归一化MTOR活性均约高两倍。
  • CLL细胞是支链氨基酸(BCAAs)的活跃消耗者,BCAT1参与双向底物反应。
  • BCAT1异常表达CLL对Venetoclax诱导凋亡敏感性降低;三个BCAT1破坏的CLL细胞系体外生长显著减少。

关键数值与推荐

  • BCAT1在del17p/TP53mut CLL中表达率66%。
  • BCAT1在12三体CLL中表达率77%。
  • BCAT1高表达对无表达原发性CLL的p-S6K归一化MTOR活性约高两倍。
  • 任何可检测BCAT1蛋白者中位生存125个月对无BCAT1蛋白者296个月(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed gene expression profiling of mRNA/cDNA isolated from N = 117 flow sorted CLL. We detected aberrant expression of the metabolic enzyme branched chain amino acid transferase (BCAT1) in CLL with del17p/TP53mut. Through extensive validation, we confirmed the highly preferential expression of BCAT1 in CLL with del17p/TP53mut (66%) or trisomy 12 (77%). BCAT1 was not expressed in B cells isolated from normal human lymph nodes. The products of the bidirectional BCAT1 reaction, including leucine, acetyl-CoA, and alpha-ketoglutarate are known activators of MTOR. We measured an ~two-fold higher MTOR activity via normalized p-S6K levels in primary CLL with BCAT1 high versus absent expression before and after sIgM crosslinking. Through steady state metabolomics and heavy isotope metabolic tracing in primary CLL cells, we demonstrate that CLL cells are avid consumers of branched chain amino acids (BCAAs) and that BCAT1 in CLL engages in bidirectional substrate reactions. Of additional interest, CLL with aberrant BCAT1 expression were less sensitive to Venetoclax-induced apoptosis. Biologically, three CLL-derived cell lines with disruption of BCAT1 had substantially reduced growth ex vivo. Clinically, the expression of any detectable BCAT1 protein in CLL independently associated with shorter median survival (125 months versus 296 months; p < 0.0001), even after exclusion of del17p/TP53mut cases.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shao Q, Wykretowicz J, Hu N, et al. Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia. Leukemia. 2024. PMID: 39455853. doi:10.1038/s41375-024-02448-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。